Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 61st Society of Thoracic Surgery Annual Meeting
Provided By PR Newswire
Last update: Jan 27, 2025
Full IDE Data Set Demonstrates Sustained Benefit at One Year with Use of AMDS in Acute DeBakey Type I (ADTI) Dissections Complicated by Malperfusion
ATLANTA, Jan. 27, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from the AMDS PERSEVERE clinical trial (the "IDE") was presented in a Late-Breaking Science presentation at the 61st Annual Meeting of the Society of Thoracic Surgeons in Los Angeles, California. The data presented analyzed clinical outcomes across the full 93 study participant IDE cohort at one year following AMDS implantation.
Read more at prnewswire.com
